Back

The efficacy and safety of pulsed-field ablation in para-Hisian paroxysmal supraventricular tachycardia: first-in-human pilot trial

3 December 2022 (08:42 - 08:54)
Organised by:
Congress Presentation Part of: Late-Breaking Science Treatment ESC Professional Premium Access ESC Asia 2022 with APSC & AFC

About the speaker

Photo
Ms Fanghui Li

West China Hospital, Sichuan University, Chengdu (China)

2 More presentations in this session

Presentation thumbnail
Multicenter registry of the Watchman left atrial appendage closure device for patients with atrial fibrillation in Japan: The TERMINATOR registry
Doctor T. Matsumoto (Kamakura, JP)
Abstract Video
Presentation thumbnail
Prasugrel-based de-escalation vs. conventional therapy after percutaneous coronary intervention in ACS patients according to the renal function
Doctor H. Kim (Seoul, KR)
Abstract Video

Access the full session

Session thumbnail
Late-Breaking Science
Video

The Event

Event poster

ESC Asia 2022 with APSC & AFC

3 December 2022 08:42 CET
You may be interested in
thumbnail
Congress Presentation
Pulsed field ablation for atrial fibrillation: acute procedural efficacy and safety of an initial german multicenter experience
27 August 2022
thumbnail
Congress Presentation
Novel focal-bipolar pulsed field ablation for treatment of accessory pathways located near the bundle of his
12 April 2026
thumbnail
Congress Presentation
Systematic review and meta analysis of clinical effectiveness safety and midterm recurrence of ventricular pulsed field ablation
14 April 2026
thumbnail
Congress Presentation
Focal pulsed field ablation of septal ventricular tachycardia in structural heart disease: a fast and effective approach
14 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources